<DOC>
	<DOCNO>NCT01421355</DOCNO>
	<brief_summary>Specific Aim : To establish feasibility study change endothelial function cause induced moderate hyperbilirubinemia type 1 diabetes . Atazanavir , drug inhibits bilirubin conjugation , use induce moderate hyperbilirubinemia . Endothelial function measure atazanavir therapy . In addition , plasma marker antioxidant capacity oxidant stress measure proof-of-concept induced moderate hyperbilirubinemia favorable effect oxidative stress type 1 diabetes .</brief_summary>
	<brief_title>A Pilot Study Moderate Hyperbilirubinemia Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Diabetes mellitus ( DM ) associate markedly increase risk macro- microvascular disease . Excess pro-oxidants insufficient antioxidant contribute oxidant stress DM . Oxidant stress induces endothelial dysfunction , major determinant vascular damage . In DM , hyperglycemia elevate free fatty acid ( FFAs ) induce generation reactive oxygen specie ( ROS ) stimulate protein kinase C ( PKC ) nicotinamide adenine dinucleotide phosphate ( NADPH ) oxidase ( Figure 1 ) . In addition , hyperglycemia activate renin-angiotensin system , angiotensin II ( Ang II ) additively stimulate PKC NADPH oxidase . Bilirubin , long regarded metabolic waste , , fact , potent antioxidant scavenger ROS . It also directly inhibit protein kinase C NADPH oxidase system , augment antioxidant activity ( Figure 1 ) . Moreover , bilirubin inhibits Ang II-mediated vasoconstriction ROS generation . Experimental model suggest hyperbilirubinemia may preserve diabetes-associated endothelial function prevent vasculopathy . Furthermore , epidemiological study demonstrate high bilirubin level associate reduce risk vascular disease DM . Bilirubin therefore emerges potentially critical molecule protect diabetic vascular renal damage . However , limited translational research address raise bilirubin level preventive therapy vascular disease DM . Accordingly , investigator seek establish feasibility study change endothelial function cause induced moderate hyperbilirubinemia type 1 diabetes . investigator take advantage recently describe use atazanavir safely achieve moderate hyperbilirubinemia . Atazanavir protease inhibitor use treat HIV infection competitively inhibit hepatic 1A1 isoform uridine diphosphoglucose glucuronosyltransferase ( UGT1A1 ) , limit bilirubin clearance induce hyperbilirubinemia ( Figure 2 ) . This mimic Gilbert 's syndrome , benign unconjugated hyperbilirubinemia due partial genetic deficiency UGT1A1 . This work potential identify iatrogenic moderate hyperbilirubinemia strategy interrupt key mechanism type 1 diabetes-associated macro- microvascular disease . This physiologic study . The design single arm open label . There three study visit : screen visit , baseline visit , final visit . The treatment atazanavir 300 mg PO bid . The treatment period 4 day . The primary study outcome forearm vascular function . The principal secondary outcome serum antioxidant defense capacity measure oxidant stress . The investigator aim study 20 subject completion 12 month funding period . The investigator anticipate enrol 40 subject 20 complete study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>1 . Symptoms diabetes plus casual plasma glucose concentration ≥ 200 mg/dl ( 11.1 mmol/l ) , ; 2 . FPG ≥ 126 mg/dl ( 7.0 mmol/l ) , ; 3 . 2h postload glucose ≥ 200 mg/dl ( 11.1 mmol/l ) OGTT . In addition , subject would require increase risk cardiovascular event , define : microalbuminuria , ; T1DM duration &gt; 20 year . 1 . HIV infection 2 . Gilbert 's syndrome 3 . Hepatic failure active hepatitis , 4 . Unstable cardiovascular disease , include angina , heart failure arrhythmia 5. drug abuse include alcoholism addiction cocaine , heroin amphetamine 6 . Use medication significantly atazanavir 7 . Pregnancy , inability practice adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>